Cost ‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines

ConclusionDapagliflozin added to standard therapy for HFrEF patients is likely to be cost-effective using the perspective of the Philippine public healthcare provider.

Source: ESC Heart Failure - September 8, 2021 Category: Cardiology Authors: Victor L. Mendoza, Bernadette A. Tumanan ‐Mendoza, Felix Eduardo R. Punzalan Tags: Original Research Article Source Type: research